UroGen Pharma (URGN) Amortizatization of Intangibles (2019 - 2026)
UroGen Pharma's (URGN) quarterly Amortizatization of Intangibles came in at $2.0 million in Q1 2026, up 155.04% YoY from $774000.0 in Q1 2025, and up 2532.0% on a QoQ basis from $75000.0 in Q4 2025.
Powered by 
Analysis
UroGen Pharma (URGN) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 8 years of Amortizatization of Intangibles data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 155.04% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 33.53% YoY) and the FY2025 annual result came in at $1.9 million, down 35.14% from the prior year.
- Amortizatization of Intangibles grew to $2.0 million in Q1 2026, from $75000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.3 million in Q3 2024 to a low of -$961000.0 in Q1 2024.
- A 5-year average of $560470.6 and a median of $355000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 2420.75% in 2024, down 337.87% in 2024.
- Tracing URGN's Amortizatization of Intangibles over 5 years: stood at $677000.0 in 2022, then slumped by 92.17% to $53000.0 in 2023, then soared by 2420.75% to $1.3 million in 2024, then plunged by 94.39% to $75000.0 in 2025, then jumped by 2532.0% to $2.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $2.0 million (Q1 2026), $75000.0 (Q4 2025), and $160000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | -796,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -796,000.00 |
| Mar 31, 2026 | 1.97 Mn |
| Dec 31, 2025 | 304,000.00 |
| Sep 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 866,000.00 |
| Mar 31, 2025 | 774,000.00 |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 223,000.00 |
| Mar 31, 2024 | -961,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Sep 30, 2023 | 222,000.00 |
| Jun 30, 2023 | 355,000.00 |
| Mar 31, 2023 | 404,000.00 |
| Dec 31, 2022 | 677,000.00 |
| Sep 30, 2022 | 594,000.00 |
| Jun 30, 2022 | 201,000.00 |
| Mar 31, 2022 | 282,000.00 |
| Dec 31, 2021 | 238,000.00 |
| Sep 30, 2021 | 235,000.00 |